Chemical Compound

Acetate

Acetate ion (C2H3O2−)

Evidence TierDWADA NOT PROHIBITED

tuneTypical Dose

No validated supplemental range for cognition/performance

watchEffect Window

No validated effect window for supplementation outcomes

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Acetate is a short chain fatty acid produced by gut fermentation of dietary fiber. It is used to support colon health, barrier integrity, and metabolic signaling.

SCFAs fuel colonocytes and influence immune and epigenetic signaling in mechanistic research. Human studies using SCFA salts report variable effects on bowel symptoms, insulin sensitivity, and inflammatory biomarkers. Minority work explores appetite hormones and blood pressure, with limited replication. Odor, taste, and gastrointestinal discomfort often limit higher doses.

Metabolic SCFA intermediary that can convert to acetyl-CoA and participates in energy pathways. Human supplement-quality evidence remains indirect and mostly non-interventional.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • No validated stand-alone cognition/performance effect demonstrated
  • Metabolic tracer utility in human physiology testing contexts

Secondary Outcomes

  • Variable GI tolerance
  • Formulation quality drives safety profile

Safety

Contraindications and Interactions

Contraindications

  • Severe renal impairment
  • Acid-base disorders
  • Severe GI disease

Side effects

  • GI upset
  • Bloating
  • Acid-base perturbation (high-dose risk)

Interactions

  • Electrolyte-altering drugs/supplements
  • Acid-base modifying regimens
  • High-salt formula overlap

Avoid if

  • CKD/ESRD
  • Pregnancy without indication
  • Active severe GI sensitivity

Evidence

Study-level References

acetate-SRC-001Randomized crossover human food-physiology study.
Sourceopen_in_new

Matsunaga T et al., Physiol Behav. 2025;292:114837 (PMID 39892638).

Population: Healthy female adults; rice + liquid meal paradigms with sodium acetate breath test endpoint.

Dose protocol: 13C- sodium acetate breath testing with co-ingested meals.

Key findings: Demonstrates acetate tracer utility but does not establish nootropic or ergogenic benefits.

Notes: Not designed to test acetate efficacy as a nutritional intervention.

Paper content

Demonstrates acetate tracer utility; does not establish nootropic or ergogenic benefits.

acetate-SRC-002Controlled exercise physiology human study using 13C-sodium acetate breath test.
Sourceopen_in_new

Nomura S et al., Eur J Appl Physiol. 2025;125:25-35 (PMID 39453456).

Population: Healthy males undergoing hypoxia/normoxia runs.

Dose protocol: Sodium acetate breath test to estimate gastric emptying and intestinal cell damage markers.

Key findings: Supports methodological utility and general physiologic tolerability monitoring.

Notes: Same limitation: assay/measurement context rather than intervention efficacy.

Paper content

Supports methodological utility and general physiologic tolerability monitoring.

acetate-SRC-003Randomized, double-blind, crossover trial.
Sourceopen_in_new

van der Beek CM, Canfora EE, Lenaerts K, Troost FJ, Olde Damink SWM, Holst JJ, Masclee AAM, Dejong CHC, Blaak EE. Distal, not proximal, colonic acetate infusions promote fat oxidation and improve metabolic markers in overweight/obese men. Clin Sci (Lond). 2016;130(22):2073-2082. doi:10.1042/CS20160263. PMID:27439969.

Population: Overweight and obese men.

Dose protocol: Colonic sodium acetate infusion at 100 or 180 mmol/L (distal vs proximal) in crossover design

Key findings: Distal 180 mmol/L acetate infusion significantly increased fasting fat oxidation (P=0.015) and peptide YY (P=0.01). Proximal infusions had no significant effect. Demonstrates that acetate location in the colon matters for metabolic signaling.

Notes: Very small sample (n=6). Colonic infusion route, not oral supplementation. Proof-of-concept for acetate metabolic effects.

Paper content

This small randomized double-blind crossover trial delivered sodium acetate directly to the distal or proximal colon of 6 overweight/obese men. Distal colonic acetate infusion at 180 mmol/L significantly increased fasting fat oxidation (P=0.015) and peptide YY (P=0.01), while proximal infusions showed no significant metabolic effects. The study provides proof-of-concept evidence that colonic acetate can influence whole-body substrate metabolism in humans, supporting the role of gut-derived SCFA in metabolic regulation. The very small sample size limits generalizability.

acetate-SRC-004Randomized controlled crossover trial.
Sourceopen_in_new

Boets E, Gomand SV, Deroover L, Preston T, Vermeulen K, De Preter V, Hamer HM, Van den Mooter G, De Vuyst L, Courtin CM, Annaert P, Delcour JA, Verbeke KA. Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: a stable isotope study. J Physiol. 2017;595(2):541-555. doi:10.1113/JP272613. PMID:27510655.

Population: Healthy adult volunteers.

Dose protocol: 13C-labeled SCFAs delivered via colon-targeted capsules in crossover design

Key findings: Acetate had 36% systemic availability (vs 9% propionate, 2% butyrate). 24% of acetate was converted to butyrate colonically. Confirms acetate as the most systemically available gut-derived SCFA.

Notes: Pharmacokinetic/metabolic tracer study, not efficacy trial. Establishes foundational human SCFA bioavailability data.

Paper content

This crossover trial in 12 healthy subjects used 13C-labeled SCFAs delivered to the colon to quantify systemic availability. Acetate had the highest systemic availability at 36%, compared to 9% for propionate and 2% for butyrate. Approximately 24% of acetate was converted to butyrate in the colon, and less than 1% was incorporated into cholesterol. The majority of all three SCFAs was excreted as CO2 via the lungs. This study provides foundational human pharmacokinetic data on colonic SCFA absorption and metabolism, confirming acetate as the most systemically available gut-derived SCFA.

Guides

Setup

Help